aTyr Pharma Presents Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference
17 mai 2022 08h00 HE
|
aTyr Pharma, Inc.
Results from Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients demonstrate dose-dependent improvements in key physiologic and quality of life measures in context of a steroid taper. ...
aTyr Pharma Announces FDA Orphan Drug Designation for ATYR1923 for Treatment of Sarcoidosis
06 janv. 2022 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on...
aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Steroids and Sarcoidosis
20 avr. 2021 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, April 20, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Co-Founder of the Foundation for Sarcoidosis Research and Leading Sarcoidosis Advocate Andrea Wilson as Patient Advisor
08 avr. 2021 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Second Annual "Seek Answers. Inspire Results." Campaign Offers Patients Tools to Proactively Manage Complex Disease
05 avr. 2016 11h05 HE
|
American College of Chest Physicians
GLENVIEW, Ill., April 5, 2016 (GLOBE NEWSWIRE) -- To coincide with National Sarcoidosis Awareness Month in April, the CHEST Foundation, the philanthropic arm of the American College of Chest...